Science AI Journal
Medicine · Research topic

Open research questions in Hepatitis B Virus Studies

58 unresolved questions extracted from the limitations and future-work sections of 493 Hepatitis B Virus Studies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Third, the specific biological and immunological mechanisms responsible for the synergistic effect of TCM herbs on improving interferon efficacy remain unclear in this study.

    Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFNα-2b · 2026 · DOI

  • Guidelines place anti-HBc-positive patients exposed to anthracyclines in a moderate-risk band warranting on-treatment monitoring or selective prophylaxis, yet real-world data from non-prophylaxis breast cancer practice, where serial HBV DNA surveillance is often incomplete, remain scarce.

    Clinically detected hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive breast cancer patients receiving systemic therapy without antiviral prophylaxis: a two-centre descriptive cohort and nested case study · 2026 · DOI

  • One important limitation of the evidence reviewed here is its predominant reliance on cross-sectional studies, experimental models, and indirect mechanistic inference. Whether the dynamic processes proposed in this framework operate similarly within individual OBI carriers over decades remains unknown. Accordingly, the immune-mediated microcosm should presently be regarded as a hypothesis-generating framework rather than a definitive biological model. This Review proposes that long-term OBI persistence is best understood as a dynamic equilibrium emerging from coordinated interactions among viral genetic adaptation, host epigenetic regulation, and intrahepatic immune homeostasis. Disruption of this equilibrium by immunosuppression, immunosenescence, or viral immune escape may shift the system toward viral reactivation or hepatocarcinogenesis. Whether similar ecological principles contribute to other persistent infections, including HIV latency or mycobacterial persistence, remains an open question requiring direct investigation. Several priorities should guide future research. First, prospective longitudinal studies integrating spatial transcriptomics, single-cell multi-omics, and quantitative virological profiling are needed to validate the proposed immune-mediated microcosm and to identify operational biomarkers of immune equilibrium (42, 78, 82). Second, non-invasive monitoring strategies combining serum HBcrAg, pgRNA, ultrasensitive HBsAg, and fibrosis-associated biomarkers warrant evaluation for longitudinal risk stratification, although their predictive performance remains to be established (71, 80, 81, 113, 114). Third, therapeutic development should focus not only on suppressing residual viral reservoirs but also on restoring immune homeostasis. Whether antiviral platforms, including base editing, antisense oligonucleotides, and CRISPR-based approaches, can be safely combined with immune or metabolic modulation requires careful clinical evaluation (119–123). Safety and implementation remain equally important considerations.

    The immunoecology of occult hepatitis B virus infection: genetic remodeling and the immune-mediated microcosm · 2026 · DOI

  • Spatial immune architecture Cell–cell interaction mapping Identification of homeostatic windows No validated quantitative thresholds currently exist for defining the immune-mediated microcosm in OBI. The candidate parameters listed here are proposed as components of a standardized multidimensional framework for future prospective validation rather than established diagnostic criteria.

    The immunoecology of occult hepatitis B virus infection: genetic remodeling and the immune-mediated microcosm · 2026 · DOI

  • Traditional Chinese medicine (TCM) shows promise in slowing the progression of hepatitis B-related liver fibrosis/cirrhosis, but its impact on immune function remains debated.

    The efficacy of traditional Chinese medicine on immune function in patients with hepatitis B-related liver fibrosis or cirrhosis: a systematic review and meta-analysis · 2026 · DOI

  • Abstract Background/objective The combination of immune checkpoint inhibitors (ICIs) with transarterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) has emerged as a promising treatment strategy for unresectable HCC; however, the impact of concurrent antibiotic use on treatment efficacy remains controversial and poorly understood.

    Early antibiotic exposure reduces progression-free survival in unresectable hepatocellular carcinoma patients treated with TACE plus TKI and ICI therapy: a propensity score-matched analysis · 2026 · DOI

  • This study has several strengths. The matched case–control design helped control for potential confounding by vaccina- tion facility and timing, reducing variability related to service delivery context. The investigation was embedded within the national AEFI response, enhancing its programmatic relevance. Data collection incorporated both caregiver interviews and facility-level assessments, providing a multi-source perspective. Several important limitations should be acknowledged. First, the sample size was very small (12 matched pairs), which resulted in substantially limited statistical power. This is reflected in the wide confidence intervals surrounding all associ- ation estimates and the consequent inability to detect even moderate risk factors, should they exist. The small number of discordant pairs rendered the analysis particularly susceptible to instability. Given the high degree of instability in all infer- ential estimates, this study is unable to reliably confirm or refute any specific risk factor. Therefore, its primary utility lies in hypothesis generation and reinforcing the importance of safe practices. Second, the retrospective design introduces the potential for recall and information bias. Exposures such as antiseptic use and vial handling were assessed approximately one year after the vaccination event and may be subject to inaccurate recall or social desirability bias. Third, the analysis was constrained by limited variability in several key exposures. Variables with no discordant pairs (e.g., cold chain indicators) had to be excluded entirely. Given the small sample size, the analysis was limited to bivariate comparisons, and no multivariable modeling was performed to avoid overfitting and unreliable estimates. Fourth, the diagnosis of injection-site abscess was based on clinical assessment without microbiological confirmation, which could lead to outcome misclassification between infectious abscesses and sterile inflammatory reactions. Finally, reliance on routine AEFI surveillance for case identification means that underreporting cannot be excluded. The study sample may not fully represent all events that occurred during the study period. Given these limitations, the findings should be interpreted as exploratory and hypothesis-generating, not as definitive evidence of causal relationships. The primary value of this study lies in highlighting the challenges of investigating rare adverse events and reinforcing the importance of standard safe practices.

    Case-control study of risk factors for abscess development following hepatitis B vaccination in children in Timor-Leste, 2024 · 2026 · DOI

  • The following recommendations were made: 1. School health units and public health educators J Biomed Res. Clin Pract | Vol 9 | No 2 | 2026 97 For Reprint Contact: [email protected] Okpe JO*, et al., Effectiveness of Health Education on Safe Sex Practices and Hepatitis B Vaccination should incorporate structured HBV education into regular campus health programmes and orientation activities, including periodic refresher sessions to maintain and enhance students' knowledge of HBV prevention.

    Effectiveness of Health Education on Safe Sex Practices and Hepatitis B Vaccination Uptake Among Tertiary Students in Benue State · 2026 · DOI

  • Future randomized controlled stud- ies are warranted to define the most effective and safe timing for prophylactic NAs in HBV/HCV coinfected patients undergo- ing DAA therapy.

    Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study · 2026 · DOI

  • However, the benefit of implementing universal anti-HBc screening to intercept occult HBV infection remains debated, primarily due to concerns over donor loss and cost-effectiveness.

    Prevalence of anti-HBc and anti-HBs among blood donors in Guangzhou: implications for HBV screening strategies in China · 2026 · DOI

  • Background & Aims: Persistent HDV replication is associated with severe liver disease, yet predictors of spontaneous HDV RNA suppression remain poorly defined.

    Diabetes, male sex, low levels of HBsAg, HDV RNA and ALT predict spontaneous HDV suppression in chronic hepatitis D · 2026 · DOI

  • Within the limitations of this study, hepatitis B vaccination was found to provide sub- stantial seroprotection among health care workers; however, a notable proportion (10.

    Seroprotection following hepatitis B vaccination in health care workers at a dental teaching hospital in south India · 2026 · DOI

  • Training programs should be conducted for all healthcare workers regarding hepatitis B infection, including the proper use of personal protective equipment and safe handling and disposal of potentially infectious materials, in order to reduce occupational risk. Efforts should be made to achieve 100% hepatitis B vaccination coverage among healthcare workers. This can be ensured by providing free vaccination facilities and implementing that encourage or mandate institutional policies vaccination for all healthcare workers. ACKNOWLEDGEMENTS The authors are thankful to all the healthcare workers who participated in the study and to the institution for their support and cooperation.

    Assessment of hepatitis B vaccination status among healthcare workers in South Delhi: a cross-sectional study · 2026 · DOI

  • Although patients with cirrhosis or clinically suspected advanced fibrosis (F3) were excluded based on ultrasound and routine testing, the exact distribution of fibrosis stages (F0–F2) remains unknown.

    HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment · 2026 · DOI

  • This study only depicts vaccination coverage and immunity at a single point in time; long-term trends are not captured.

    Estimation of Hepatitis B vaccination status and immune response among healthcare <span style="font-size: 1rem;">workers in a Tertiary Care South Indian Hospital</span> · 2026 · DOI

  • Need for multidisciplinary team guidelines: While the paper emphasizes MDT discussion for treatment decisions, formal clinical guidelines for MDT coordination in managing concurrent CDK4/6 inhibitor therapy and chronic HBV infection are not established.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Insufficient data on long-term outcomes after HBV reactivation recovery: The paper lacks information on long-term follow-up data for patients who experience dalpiciclib-induced HBV reactivation and subsequently recover with antiviral therapy.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Limited mechanistic understanding of dalpiciclib-induced HBV reactivation: While the paper identifies immunosuppression-driven HBV reactivation as the mechanism rather than direct toxicity, the specific immunological pathways involved remain incompletely characterized.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Need for prospective studies on antiviral prophylaxis effectiveness: The conclusion underscores the need for antiviral prophylaxis over passive enzyme monitoring, but systematic prospective studies comparing prophylactic antiviral strategies in dalpiciclib-treated HBV carriers are lacking.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Unclear optimal dosing strategies for CDK4/6 inhibitor rechallenge: While the paper recommends initiating alternative CDK4/6 inhibitors at reduced doses with intensive monitoring, specific dose reduction guidelines and monitoring protocols for HBV carriers are not well-established.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Limited data on alternative CDK4/6 inhibitor safety profiles in HBV carriers: The paper mentions that switching to alternative CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) may be considered but lacks comprehensive comparative data on hepatotoxicity risk across different agents in HBV-positive populations.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Need for comprehensive pre-treatment evaluation protocols: While the paper emphasizes mandatory HBsAg and/or HBV DNA level assessment prior to dalpiciclib initiation, standardized screening and risk stratification protocols across different clinical settings remain undefined.

    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature · 2026 · DOI

  • Although our previous studies have revealed that the anti-hepatitis B virus (anti-HBV) activity of BA depends on hepatocyte nuclear factor (HNF) signaling, the specific mechanisms remain unclear.

    Sequential activation of ERα-AMPKα signaling by the flavonoid baicalin down-regulates viral HNF-dependent HBV replication · 2024 · DOI

  • </ns4:p> <ns4:p> <ns4:bold>Conclusion</ns4:bold> : Stigma is a potentially major barrier to the successful implementation of preventive, diagnostic and treatment strategies for HBV infection, and yet we highlight a ‘blind spot’, representing a lack of data and limited recognition of this challenge.

    A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review · 2018 · DOI

  • Currently, little is known about how African-Australians living with CHB understand their condition, their risk of liver cancer and the need for regular monitoring.

    Knowing and telling: how African-Australians living with chronic hepatitis B understand hepatocellular carcinoma risk and surveillance · 2018 · DOI

Most-cited papers in Hepatitis B Virus Studies

Most recent work

Find a gap in your own Hepatitis B Virus Studies sub-topic

This page shows what the Hepatitis B Virus Studies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
58 open questions have been extracted from the limitations and future-work passages of 493 Hepatitis B Virus Studies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.